Although srKD003 has limited application for tumors resistant to immune checkpoint inhibitors, its cognate, IL-15-based PD-L1-targeted immunocytokine LH01, can overcome primary resistance to PD-1/PD-L1 blockade by down-regulating TGF- levels within a tumor microenvironment, with no significant effect on PD-L1 expression levels. This evidence concerns the gene CD274 and neoplasm.